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A 68-year-old man was introduced to our hospital for the treatment of lung and mediastinum lymph
node metastases that originated from an urachal carcinoma 4 years after a partial cystectomy. First-line
chemotherapy with an S-1 and cisplatin combination was ineffective. The patient received FOLFIRI plus
bevacizumab chemotherapy as salvage chemotherapy. Stability was achieved after eight cycles of FOLFIRI
plus bevacizumab therapy. We conducted a biopsy of the metastatic tumor, and the pathology of the
biopsy tissue was partially necrotic. To our knowledge, this case represents the ﬁrst report of a metastatic
urachal carcinoma treated with FOLFIRI plus bevacizumab.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
To date, no randomized trials and fewer than 300 cases of urachal
carcinomas have been reported in the literature. As a result, limited
information exists regarding the effective management of these
cancers, especially knowledge concerning the most effective
chemotherapeutic agents against atypical bladder cancers with his-
tological and biological features similar to those of bowel cancers.
Most urachal carcinomas are mucin-producing enteric type adeno-
carcinomas that occasionally may exhibit signet ring cells
morphology.1 The prognosis of patients with recurrent urachal car-
cinoma is extremely poor. We report a case of metastatic urachal
carcinoma inwhich the immunohistochemical proﬁle’s similarities to
that of colon cancer led to treatment with FOLFIRI plus bevacizumab,
which is a speciﬁc ﬁrst-line chemotherapy of colon cancer.
Case report
A 68-year-old man was introduced to our hospital for the treat-
ment of lung and mediastinum lymph node metastases originating
from an urachal carcinoma. He had undergone a partial cystectomy
for this urachal carcinoma 4 years ago. After no evidence of: þ81 6 6647 4426.
uchi).
Inc. This is an open access article urecurrence for 2 years, he ceased follow-up examinations. The pa-
tient then presented dyspnea, and computed tomography (CT)
revealed multiple lung tumors and an anterior mediastinum mass
(Fig.1), whichwas diagnosed asmetastases of urachal carcinoma by
thoracoscopic biopsy. Colonoscopydenied primary colon cancer and
the serum levels of carcinogen embryonic antigen and carbohydrate
antigen 19-9 were within normal ranges. This pathology revealed a
mucinous adenocarcinoma with a pathology similar to that of the
primary urachal carcinoma (Fig. 2(a and b)). On immunohisto-
chemical staining, the tumor was positive for cytokeratin-20, cyto-
leratin-7, and caudaletype homeobox transcription factor 2.
However, the tumor was negative for thyroid transcription factor-1
and napsin A. From the results of immunohistochemical staining,
the patient was diagnosed with a recurrence of urachal carcinoma.
The patient was treated with S-1 and cisplatin combination (S-1/
CDDP) chemotherapy (S-1 was administered orally at a dose of
120mg/day for 14 days, and CDDPwas infused at a dose of 120mgon
day 8 of each 28-day cycle) as a ﬁrst-line chemotherapy. After three
cyclesofS-1/CDDP,CTrevealedan increaseof lungmetastases, andwe
assessed progressive disease (PD). We changed the treatment
regimen to FOLFIRI þ bevacizumab as a salvage chemotherapy (bev-
acizumab 5 mg/kg, irinotecan 180 mg/m2, l-leucovorin 200 mg/m2,
ﬂuorouracil 400 mg/m2, and bolus 2400 mg/m2/46 h of each 14 days
cycle) under careful informed consent and the approval of the insti-
tutional review board of Osaka City University. Radiographicnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Figure 1. Chest computed tomography conducted before chemotherapy shows mul-
tiple lung tumors and the anterior mediastinum mass.
T. Kanamaru et al. / Urology Case Reports 3 (2015) 9e1110evaluation, performed every two cycles, revealed stable disease (SD)
in the lung and anterior mediastinum metastases. After eight cycles,
the lung and anterior mediastinummetastases remained stable, and
we performed a biopsy of the anterior mediastinum metastases to
evaluate viable tumor cells. Thepathologicalﬁndings showedamixof
viable cells and necrotic tissuewith a large amount of mucin, and we
thus assessed the chemotherapy as partially effective. However, we
had to give the patient a washout period because of general fatigue
(grade 2, CTCAE v4.0) and severe diarrhea (grade 3, CTCAE v4.0)
despite using the maximum doses of loperamide hydrochloride and
hangeshashinto (TJ-14, aKampomedicine),which reduces the level of
prostaglandin E2 and affects cyclooxygenase activity, thereby allevi-
ating chemotherapy-induced oral mucositis.2 After 6 months, CT
revealed increased lung metastasis and we recommended further
chemotherapy, but thepatientdeclined this suggestionbecauseof the
severe diarrhea caused by irinotecan and decided to undergo pallia-
tive care. After 8 months, he died of further disease progression. The
second-line chemotherapy regimen of FOLFIRI plus bevacizumab led
to 12 months of progression-free survival and 20 months of overall
survival after the failure of ﬁrst-line chemotherapy.Discussion
To date, no recommended chemotherapy regimen has been
established for metastasis or unresectable urachal carcinoma. We
choose S-1/CDDP for ﬁrst-line chemotherapy in this case because S-Figure 2. (a) Pathology of primary urachal carcinoma stained with hematoxylin and eosin (m
with hematoxylin and eosin (magniﬁcation 400).1 is an oral 5-FU derivative consisting of tegafur, gimeracil, and
oteracil. The clinical effect of 5-FU is known to be enhanced by
combination with CDDP, and effective response rates for S-1/CDDP
combination chemotherapy have been reported for esophageal,
gastric, and lung cancer; two cases have shown good responses to
S-1/CDDP chemotherapy for urachal carcinoma.3 Unfortunately, S-
1/CDDP chemotherapy led to no positive response in the present
case.
Recently, several cases of urachal carcinoma chemotherapy
based on irinotecan or oxaliplatin have been reported; these
treatments were employed because urachal adenocarcinomas are
often histologically similar to adenocarcinomas from the gastroin-
testinal tract. Irinotecan is a topoisomerase 1 inhibitor that disrupts
cell division by interfering with DNA replication and has demon-
strated preclinical activity in adenocarcinomas from a variety of
tumor types, including gastric, colorectal, pancreatic, lung, and
breast carcinomas. Currently, FOLFIRI (irinotecan in combination
with 5-FU/leucovorin) with or without bevacizumab is indicated as
a ﬁrst-line chemotherapy for metastatic colon cancer,4 and FOLFOX
(oxaliplatin, leucovorin, and ﬂuorouracil) with or without bev-
acizumab is another ﬁrst-line chemotherapy for metastatic colon
cancer. The efﬁcacy of FOLFOX against urachal carcinoma has
recently been reported in several case reports.5 Because we used
platinum-based chemotherapy as the ﬁrst-line treatment in this
case, we choose FOLFIRI rather than FOLFOX for second-line
chemotherapy. Bevacizumab is a recombinant humanized mono-
clonal IgG1 antibody that binds to and inhibits the biological ac-
tivity of the human vascular endothelial growth factor (VEGF). The
NCCN Guidelines for colon cancer recommend that bevacizumab
should be added to FOLFIRI or FOLFOX for advanced or metastatic
colon cancer.4 We therefore chose to add bevacizumab to FOLFIRI in
this case.
Unfortunately, we were unable to perform a pathological
autopsy, but the biopsy tissue from the anterior mediastinum
metastases after eight cycles of FOLFIRI plus bevacizumab
chemotherapy revealed a mix of viable cells and necrotic tissue,
with a large amount of mucin. Therefore we conclude that
FOLFIRI plus bevacizumab led to 12 months of progression-free
survival and 20 months of overall survival after the failure of
ﬁrst-line chemotherapy. This case represents the ﬁrst report of
metastatic urachal carcinoma treated with FOLFIRI plus bev-
acizumab, indicating its potential as a second-line chemotherapy
for this disease.
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